Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – C-o-group doai
Patent
1997-06-16
1999-12-07
Criares, Theodore J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
C-o-group doai
514728, 514103, A61K 31045
Patent
active
059984856
ABSTRACT:
A composition for modulating immune response in mammals, comprises a therapeutic agent such as a stereoisomer of inositol, derivatives, salts, and mixtures thereof, and optionally a carrier. The composition is provided in solid and liquid formulations, including solutions, suspensions, spreadable and solid forms, as an implant, inhalant, and in vaporizable, injectable, oral and transdermal forms, and the like. The composition of the invention is useful for modulating (enhancing/inhibiting) the immune response. The therapeutic agent of this invention enhances/suppresses B and/or T lymphocyte activity(ies) in normal, aging and immunodeficient mammals, as well as those afflicted with auto-immune disease (s), or subjected to transplants.
REFERENCES:
patent: 5051411 (1991-09-01), Siren
patent: 5082833 (1992-01-01), Shamsuddin
patent: 5342832 (1994-08-01), Siren
Asplin, et al. "chiro-Inositol deficiency and insulin resistance: A comparison of the chiro-inositol-and the myo-inositol-containing insulin mediators isolated from urine, hemodialysate, and muscle of control and type II diabetic subjects," Proc. Natl. Acad. Sci. USA, 90:5924-5928 (Jul. 1993).
Atack, et al., "Characterization of the effects of lithium on phosphatidylinositol (PI) cycle activity in human muscarinic m1 receptor-transfected CHO cells," Brit J.. Pharmacology, 110:809-815 (1993).
Baten, et al., "Inositol-phosphate-induced enhancement of natural killer cell activity correlates with tumor suppression," Carcinogenesis, 10(9):1595-1598 (1989).
Bento, et al., "Glycoinositolphospholipids Purified from Trypanosoma cruzi Stimulate lg Production In Vitro," J. Immunol., 157:4996-5001 (1996).
Berridge, Michael J., "Inositol trisphosphate and calcium signalling," Nature, 361:315-325 (Jan. 1993).
Berridge, Michael J., "Inositol Trisphosphate and Diacylglycerol: Two Interacting Second Messengers," Ann. Rev. Biochem, 56:159-193 (1987).
Bruzik, et al., "Are-D-and L-chiro-Phosphoinositides Substrates of Phosphatidylinositol-Specific Phospholipase C?," Biochemistry, 33:8367-8374 (1994).
Galasko, et al., "Circulating Factors and Insulin Resistance. I.A. Novel Myoinositol 1,2-Cyclic Phosphate Phosphoglycan Insulin Antagonist from Human Plasma Is Elevated in Noninsulin-Dependent Diabetes Mellitus," Jour. Clin. Endocrinology and Metabolism, 80(5):2419-2429 (1995).
Hallman, et al., "Inositol Supplementation in Premature Infants with Respiratory Distress Syndrome," N. Engl. J. Med., 326(19):1233-1239 (1992).
Hansbro, et al., "Kinetic Analysis of Novel Inhibitors of Inositol Polyphosphate Metabolism," Biochemical and Biophyical Research Comm.,200(1):8-15 (Apr. 15, 1994).
Huang, et al., Chiroinositol Deficiency and Insulin Resistance. III. Acute Glycogenic and Hypoglycemic Effects of Two Inositol Phosphoglycan Insulin Mediators in Normal and Streptozotocin-Diabetic Rats in Vivo, Endocrinology, 132(2):652-657 (1993).
Johnson, et al., "Synthesis and Evaluation of 3-Modified 1D-myo-Inositols as Inhibitors and Substrates of Phosphatidylinositol Synthase and Inhibitors of myo-Inositol Uptake by Cells," J. Med. Chem., 36:3628-3635 (1993).
Johnson, et al., "Synthesis of the 3-deoxy-3-C-(phosphonomethyl) analogue of 1D-myo-inositol 3-(dihydrogenphosphate)," Carbohydrate Research, 250:315-321 (1993).
Kofman, et al., "Myo-inositol attenuates the enhancement of the serotonin syndrome by lithium," Psychopharmacology, 118:213-218 (1995).
Mason, et al.,, "A neurophysiological study of a lithium-sensitive phosphoinositide system in the hamster suprachiasmatic (SCN) biological clock in vitro," Neuroscience Letters, 144:135-138 (1992).
Morris, et al., "Phosphatidylinositol Phospholipase C Is Activated Allosterically by the Aminoglycoside G418," Journal of Bio. Chem, 271(26)15468-15477 (Jun. 28, 1996).
Ortmeyer, et al., "Chiroinositol Deficiency and Insulin Resistance. I. Urinary Excretion Rate of Chiroinositol Is Directly Associated with Insulin Resistance in Spontaneously Diabetic Rhesus Monkeys," Endocrinology, 132(2):640-645 (1993).
Ortmeyer, et al., "Chiroinositol Deficiency and Insulin Resistance. II. Acute Effects of D-Chiroinositol Administration in Streptozotocin-Diabetic Rats, Normal Rats Given a Glucose Load, and Spontaneously Insulin-Resistant Rhesus Monkeys," Endocrinology, 132(2):646-651 (1993).
Ostlund, Jr., et al., "D-chiro-Inositol metabolism in diabetes mellitus," Proc. Natl. Acad. Sci. USA, 90:9988-9992 (Nov. 1993).
Ostlund, Jr., et al., "A Stereospecific myo-Inositol/D-chiro-Inositol Transporter in HepG2 Liver Cells," Journal of Biological Chemistry, 271(17):10073-10078 (Apr. 26, 1996).
Pak, et al., "Insulin stimulates the biosynthesis of chiro-inositol-containing phospholipids in a rat fibroblast line expressing the human insulin receptor," Proc. Natl. Acad. Sci. USA, 90:7759-7763 (Aug. 1993).
Raffa, et al., "Morphine antinociception is mediated through a LiCI-sensitive, IP.sub.3 -restorable pathway," European Jour. of Pharmacology, 215:357-358 (1992).
Raffa, et al., "Opioid efficacy is linked to the LiCI-sensitive, inositol-1,4,5-trisphosphate-restorable pathway," European Jour. of Pharmacology, 217:221-223 (1992).
Shamsuddin, et al., "Inositol and inositol hexaphospnate suppress cell proliferation and tumor formation in CD-1 mice," Carcinogenesis, 10(8):1461-1463 (1989).
Suzuki, et al., "Urinary chrio-Inositol Excretion is an Index Marker of Insulin Sensitivity in Japanese Type II Diabetes," Diabetes Care, 17(12):1465-1468 (Dec. 1994).
Tagliaferri, et al., "1L-2,3:4,5-Bis-O-(tetraisopropyldisiloxane-1,3-diyl)-chiro-inositol: a useful intermediate for the preparation of several novel cyclitols," Carbohydrate Research, 266:301-307 (1995).
Tyan, Marvin L., "Inhibition of in Vitro Immune Responses by Antisera to H-2 or Ir Gene Products," Proceedings of the Society for Exper. Bio. and Med., 150:313-317 (1975).
Weetman, et al., "The Enhancement of Immunoglobulin Synthesis by Human Lymphocytes with Lithium," Clinical Immunology and Immunopathology, 22:400-407 (1982).
Weiss, A., et al., "The Role of T3 Surface Molecules in the Activation of Human T Cells: A Two-Stimulus Requirement for IL 2 Production Reflects Events Occurring at a Pre-Translational Level", J. Immunol., 133(1): 123-127, (1984).
Duke, R.C., et al., "Cytotoxic Lymphocyte-Derived Lytic Granules Do Not Induce DNA Fragmentation In Target Cells", J. Immunol., 141(7): 2191-2194, (1988).
Devos, R., et al., "Induction of Cytolytic Cells by Pure Recombinant Human Interleukin 2", Verlag Chemie GmbH.D.-40 Weinheim, pp. 1057-1060. (1980).
Berkower, I., et al., "T Cell Clones to Two Major T Cell Epitopes of Myoglobin: Effect of I-A/I-E Restriction on Epitope Dominance", J. Immunol., 135(4): 2628-2634, (1985).
Schmid, D.S., "The Human MHC-Restricted Cellular Response to Herpes Simplex Virus Type 1 is Mediated by CD4.sup.+, CD8.sup.- T Cells and is Restricted to the DR Region of the MHC Complex", J. Immunol., 140(10): 3610-3616, (1988).
Jacobson, S., et al., "Measles Virus-Specific T4.sup.+ Human Cytotoxic T Cell Clones are Restricted by Class II HLA Antigens", J. Immunol., 133(2): 754-757, (1984).
Golstein, P., "Sensitivity of Cytotoxic T cells to T-Cell Mediated Cytotoxicity", Nature, 252: 81-83, (1974).
Marrack, P., et al., "The Development of Helpter T Cell Precursors in Mouse Thymus", J. Immunol., 140(8): 2508-2514, (1988).
Urban, J.L., et al., "Restricted Use of T Cell Receptor V Genes in Murine Autoimmune Encephalomyelitis Raises Possibilities for Antibody Therapy", Cell, 54: 577-592, (1988).
Pacific Basin Gathering in Hawaii Fills with Chemists, Meeting Briefs Science, vol. 271:145-146, (1996).
Wilcox, A., et al. "Modification at C2 of Myo-Inositol, 1,4,5-Triphosphate Produces Inositol Phosphates and Tetrakisphosphates with Potent Biological Activites", Biochem.223: 115-124 (1994).
Downes, C.P., et al. "Studies of Inositol Analogues as Inhibitors of the Phosphoinositide Pathway, and Incorporation of 2-Deoxy-2-Fluoro-Myo-Inositol to Live Analogues of Phosphatidylinositol Intermediates", Chem. J., 277: 407-412, (1991).
Lampe, D., et al., "Synthesis of Selective Non-ca.sup.2+ -Mobili
Tyan Dolly B.
Tyan Marvin L.
Amzel Viviana
Cedars-Sinai Medical Center
Criares Theodore J.
LandOfFree
Method for modulating immune response with inositol does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for modulating immune response with inositol, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for modulating immune response with inositol will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-824611